Discovery of an orally bioavailable selenium-containing Polθ inhibitor with a dual mechanism of DNA damage and immune activation for HR-deficient cancers

European Journal of Medicinal Chemistry 2026

View at publisher

Authors: Luyu Ma, Mingjin Luo, Mingjin Luo, Xiangchi Liu, Jinyue Yang, Jianyu Li, Mingzhe Zhong, Xinyan Liu, Maoxu Xiao, Hua Xiang, Guoshun Luo

DOI: 10.1016/j.ejmech.2026.118887

Cited by: 3

References: 42

Fields of Study & Subjects

interferon and immune responses Cancer Immunotherapy and Biomarkers PARP inhibition in cancer therapy

References 42